Integris Medtech IPO: dates, price band, lot size and GMP

Integris Medtech IPO opens 27 Nov – 1 Dec 2026 on the Mainboard, price band Band awaited, lot size awaited, no GMP reported yet. Allotment 2 Dec, listing 4 Dec.

Listing date: Integris Medtech IPO is scheduled to list on 4 Dec on NSE, BSE.

Updated 20 Nov 2026, 18:03 IST. Dated dealer references.

BuyUnlistedShares tracks 229 IPOs on its calendar; the Integris Medtech IPO has a price band of Band awaited, a lot of — shares and no grey-market premium reported yet as of 20 Nov 2026.

Key details

Integris Medtech IPO key details
BoardMainboard
Issue dates27 Nov – 1 Dec 2026
Price bandBand awaited
Fresh issue₹600 Cr
Subscription—
RegistrarKfin Technologies Ltd.
Lead managersICICI Securities Ltd., Axial Capital Pvt.Ltd., Citigroup Global Markets India Pvt.Ltd., IIFL Capital Services Ltd.
StatusUpcoming

Timeline

  1. Issue opens: 27 Nov
  2. Issue closes: 1 Dec
  3. Allotment: 2 Dec
  4. Refunds: 3 Dec
  5. Demat credit: 3 Dec
  6. Listing: 4 Dec

Issue details

Integris Medtech IPO issue details
Face value₹1
Issue typeBook Build Issue
Listing atNSE, BSE
Offer for sale (shares)1,08,37,266
Promoter holding pre-issue83.24%
PromotersEvercure Holdings Pte.Ltd., Medicore Holdings Pte.Ltd., Gurmit Singh Chugh and Punita Sharma
Lead managersICICI Securities Ltd., Axial Capital Pvt.Ltd., Citigroup Global Markets India Pvt.Ltd., IIFL Capital Services Ltd.
Registrar phone040-79615565
Registrar emailintegris.ipo@kfintech.com
Company websiteintegrismedtech.com
Anchor bid date26 Nov 2026
Anchor lock-in ends (50%)1 Jan 2027
Anchor lock-in ends (remaining)2 Mar 2027

Reservation

Integris Medtech IPO reservation by category
CategoryShare of issueShares offeredBasis
QIB——Not less than 75% of the Offer
NII (HNI)——Not more than 15% of the Offer
Retail——Not more than 10% of the Offer

Key ratios as of 31 Mar 2025

Integris Medtech IPO key ratios
EPS (pre-issue)₹6.52
RoNW1.48%
RoCE14.51%
RoE5.35%
PAT margin3.72%
EBITDA margin16.26%
NAV per share₹316.09

Financials (₹ Cr)

Integris Medtech financials as filed, ₹ Cr
Metric30 Jun 2025FY25FY24FY23FY25 vs FY24
Assets4,019.623,641.342,989.22,553.87+21.8%
Total Income508.931,959.581,582.261,369.66+23.8%
Profit After Tax267.5770.68−4.88−40.54loss to profit
EBITDA78.73309.4190.45168.82+62.5%
NET Worth3,889.992,752.522,681.022,629.52+2.7%
Reserves and Surplus2,299.841,150.741,135.711,073.12+1.3%
Total Borrowing793.421,729.46813.1556.54+112.7%

About Integris Medtech

Incorporated in 2008, Integris Medtech Ltd is a diversified India-based global medical products and laboratory solutions company. The company develops, manufactures, commercialises, and sells a broad portfolio of medical devices and solutions spanning cardiovascular devices, clinical diagnostics, and scientific laboratory solutions.

Integris Medtech operates manufacturing facilities in India, Germany, and the Netherlands, supplying products to more than 65 international markets across India, Europe, and Southeast Asia. Its customer base includes over 9,500 laboratories and 2,000 hospitals and cathlabs, supported by a portfolio exceeding 22,000 SKUs across more than 200 brands in laboratory and cardiovascular segments.

The company's business is structured into two core divisions:

Integris Medtech supports laboratories and hospitals across India, Singapore, Thailand, Malaysia, and the Philippines, serving both public and private sectors.

Its European operations focus primarily on cardiovascular products, including proprietary brands like Chrome and Protégé, while its Rest of World presence spans the Middle East, Africa, and Latin America.

As of June 30, 2025, Integris Medtech employed 1,879 personnel, including sales, service, and application specialists, and had supported more than 15,000 patients across 100+ clinical trial sites globally, reinforcing its commitment to clinical evidence and innovation in MedTech solutions.

Objects of the issue

  1. Repayment/ prepayment, in full or in part, of certain outstanding borrowings, interest accrued and prepayment penalties, as applicable, availed by: — ₹509.85 Cr
  2. The wholly-owned Subsidiaries, namely, Translumina Therapeutics Pvt.Ltd. (Translumina Therapeutics), Transhealth Pvt.Ltd. (Transhealth) ) and HaleMed Medical Pvt.Ltd. — ₹93.87 Cr
  3. The step-down Subsidiaries, namely, CPC Diagnostics Pvt.Ltd., Chemopharm Sdn. Bhd., Chemoscience Pte Ltd., Lifeline Diagnostics Supplies Inc., Hausen Bernstein Co. Ltd, Medigene Sdn. Bhd., Research Instruments Sdn Bhd and Research Instruments Pte. Ltd. — ₹415.98 Cr
  4. General Corporate Purposes

Net proceeds: ₹1,019.7 Cr

Peer comparison

Integris Medtech IPO listed peers, financial year ended 31 Mar 2025
CompanyEPS (Basic)EPS (Diluted)NAV (per share) (Rs)P/E (x)RoNW (%)P/BV RatioFinancial statements
Our Company5.825.73316.09—1.84%—Consolidated
Poly Medicure34.1334.11278.4656.02x12.26%6.87Consolidated
Laxmi Dental6.076.0537.7153.95x16.09%8.81Consolidated

Notes: Closing Price per share is closing price in NSE as on October 8, 2025. P/E has been computed as market price per share as on October 8, 2025 divided by net diluted earnings per share for the year ended March 31, 2025. Basic EPS (₹) = Basic earnings per share are calculated by dividing the net restated profit or loss for the year attributable to equity shareholders by the weighted average number of Equity Shares outstanding during the year.

Risk factors (as disclosed by the company)

From the RHP (risk factors pages 25–46). Headings shortened; the wording is the company’s. Not a recommendation.

Offer documents: DRHP (PDF)

Track this issue

Frequently asked questions

When does the Integris Medtech IPO open and close?

The issue is scheduled for 27 Nov – 1 Dec 2026.

What is the Integris Medtech IPO price band?

The price band is Band awaited per share.

When will Integris Medtech list?

The tentative listing date is 4 Dec on the main board.

How do I apply for the Integris Medtech IPO?

Apply through your broker or bank using ASBA or UPI within the issue window; the amount stays blocked in your account until allotment. BuyUnlistedShares does not take applications; it tracks the issue and the unlisted price before it.

Sources

How to cite this page: BuyUnlistedShares, “Integris Medtech IPO”, https://buyunlistedshares.com/ipo/integris-medtech-ipo, as of 20 Nov 2026.

Other IPOs on the calendar

Indicative reference price, dated. BuyUnlistedShares is India's premium unlisted shares desk, run by Gayatri Financial Synergy LLP, in the market since 2002. Reviewed by the BuyUnlistedShares desk before publishing. Data as of 20 Nov 2026.

Guides for IPO applicants and pre-IPO holders

All unlisted shares · IPO calendar · Research & learning · Send an enquiry · Calculators · Community · Jobs · About · Contact · Privacy · Terms · Disclaimer · Grievance redressal

Guides: Start investing · Evaluate a company · How prices are set · Risks · Lock-in periods · After the IPO · Sell ESOPs · NRI investors · Buybacks · Choosing a platform

Part of the Gayatri Financial Synergy group (gayatrifin.com): AMFI-registered mutual fund distributor, Faridabad, since 2002.

BuyUnlistedShares (BUS) · Gayatri Financial Synergy LLP (LLPIN ACU-4678) · SCO-39, 1st Floor, HUDA Market, Sector-7, Faridabad, Haryana 121006 · +91 916-916-59-59

Integris Medtech IPO 2026: Dates, Price Band, Lot Size, GMP